Sumithra J. Mandrekar

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Adjuvant Nivolumab vs Observation in Resected Non–Small Cell Lung Cancer

  JAMA · 2026-06-01

• The oncology data paradigm in practice: A feasibility study of structured data capture with minimal support (stage one of a multi-phase implementation).

  Journal of Clinical Oncology · 2026-05-28

• Differences in central versus local lab PD-L1 classification in the ALCHEMIST Alliance A151216 non–small cell lung cancer (NSCLC) study.

  Journal of Clinical Oncology · 2026-05-28

• Randomized phase III study of nivolumab after surgery and adjuvant chemotherapy in NSCLC (ECOG-ACRIN EA5142, ALCHEMIST).

  Journal of Clinical Oncology · 2026-05-28

• Adjuvant erlotinib versus observation after complete resection of <i>EGFR</i> -mutant NSCLC: Final overall survival results of Alliance A081105.

  Journal of Clinical Oncology · 2026-05-28

• PRO-ADD: Patient-empowered dose-finding trials integrating safety, preliminary efficacy and patient-reported outcomes for optimal dose selection

  Statistical Methods in Medical Research · 2026-04-29

• PROSPECT-LUNG: A National Clinical Trials Network Trial Advancing Pragmatic Innovation in Cancer Clinical Trials

  Journal of Thoracic Oncology · 2026-02-01 · 2 citations

• Supplementary Table S2 from Was It Worth It? Response Data from &gt;650 US and International Participants in Chemoprevention Trials

  2026-01-06

• Supplementary Table S1 from Was It Worth It? Response Data from &gt;650 US and International Participants in Chemoprevention Trials

  2026-01-06

• Supplementary Figure S2 from Was It Worth It? Response Data from &gt;650 US and International Participants in Chemoprevention Trials

  2026-01-06

• Data from Was It Worth It? Response Data from &gt;650 US and International Participants in Chemoprevention Trials

  2026-01-06 · 1 citations

• Supplementary Figure S1 from Was It Worth It? Response Data from &gt;650 US and International Participants in Chemoprevention Trials

  2026-01-06

• Supplementary Table S4 from Was It Worth It? Response Data from &gt;650 US and International Participants in Chemoprevention Trials

  2026-01-06

• Supplementary Table S3 from Was It Worth It? Response Data from &gt;650 US and International Participants in Chemoprevention Trials

  2026-01-06

• PL02.18 Phase 3 Trial of Crizotinib vs Observation for Surgically Resected Early-Stage ALK+ NSCLC

  Journal of Thoracic Oncology · 2025-10-01 · 1 citations

• Was It Worth It? Response Data from &amp;gt;650 US and International Participants in Chemoprevention Trials

  Cancer Prevention Research · 2025-09-02 · 1 citations

• 485MO Health-related quality of life (HRQoL) from the PATINA trial (AFT-38): Impact of adding palbociclib to HER2 and endocrine therapy (ET) after induction in HR+/HER2+ metastatic breast cancer (MBC)

  Annals of Oncology · 2025-09-01 · 5 citations

• Alliance A092104: A randomized phase 2/3 study of olaparib plus temozolomide versus investigator’s choice for the treatment of patients with advanced uterine leiomyosarcoma after progression on prior chemotherapy.

  Journal of Clinical Oncology · 2025-05-28 · 4 citations

• Comparing impact of treatment before or after surgery in patients with stage II-IIIb resectable non-small cell lung cancer (NSCLC; Alliance A082304-SWOG S2402).

  Journal of Clinical Oncology · 2025-05-28 · 2 citations

• QIM25-237: Supporting Oncologists in Capturing and Using Structured Oncology Data in Real-Time Using the Electronic Health Record (EHR)

  Journal of the National Comprehensive Cancer Network · 2025-03-28